JP2016535009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535009A5 JP2016535009A5 JP2016524060A JP2016524060A JP2016535009A5 JP 2016535009 A5 JP2016535009 A5 JP 2016535009A5 JP 2016524060 A JP2016524060 A JP 2016524060A JP 2016524060 A JP2016524060 A JP 2016524060A JP 2016535009 A5 JP2016535009 A5 JP 2016535009A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- exosome
- cells
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 102000009109 Fc receptors Human genes 0.000 claims description 10
- 108010087819 Fc receptors Proteins 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- -1 antibodies Chemical class 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 claims description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229950003662 fenretinide Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892352P | 2013-10-17 | 2013-10-17 | |
| US61/892,352 | 2013-10-17 | ||
| US201462038734P | 2014-08-18 | 2014-08-18 | |
| US62/038,734 | 2014-08-18 | ||
| PCT/US2014/061245 WO2015058148A1 (en) | 2013-10-17 | 2014-10-17 | Antibody dependent exosome therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016535009A JP2016535009A (ja) | 2016-11-10 |
| JP2016535009A5 true JP2016535009A5 (enExample) | 2017-11-09 |
Family
ID=52828772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524060A Pending JP2016535009A (ja) | 2013-10-17 | 2014-10-17 | 抗体依存性エキソソーム治療の方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20160243192A1 (enExample) |
| EP (1) | EP3057662A4 (enExample) |
| JP (1) | JP2016535009A (enExample) |
| WO (1) | WO2015058148A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011097480A1 (en) | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| WO2013070324A1 (en) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
| EP3129010B1 (en) | 2014-04-11 | 2019-12-04 | University Of Louisville Research Foundation, Inc. | Coated edible plant-derived microvesicle compositions and methods for using the same |
| EP3316862A4 (en) * | 2015-07-02 | 2019-02-06 | University of Louisville Research Foundation, Inc. | MICROVESICLE COMPOSITIONS OBTAINED FROM EDIBLE PLANTS FOR THE DISTRIBUTION OF MIRNA AND METHOD FOR THE TREATMENT OF CANCER |
| US11993787B2 (en) * | 2015-11-18 | 2024-05-28 | University Of Georgia Research Foundation, Inc. | Neural cell extracellular vesicles |
| WO2017087685A1 (en) | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
| CN110662532A (zh) | 2017-04-03 | 2020-01-07 | 加利福尼亚大学董事会 | 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs) |
| US10815520B2 (en) | 2017-04-07 | 2020-10-27 | University Of Louisville Research Foundation, Inc. | Nanovesicles, methods, and systems for diagnosis and prognosis of cancer |
| EP3438250B1 (en) * | 2017-07-31 | 2022-12-07 | Rheinische Friedrich-Wilhelms-Universität Bonn | Cell derived extracellular vesicles for the treatment of diseases |
| US12036262B2 (en) | 2017-11-22 | 2024-07-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived nanoparticles for regulation of gut microbiota |
| CN110669764B (zh) * | 2017-12-11 | 2020-12-11 | 浙江大学 | 一种hsa-miR-10367 miRNA序列在抗肿瘤中的应用 |
| AU2019218991A1 (en) * | 2018-02-12 | 2020-07-09 | Lonza Sales Ag | Methods and compositions for macrophage polarization |
| IL266153A (en) * | 2019-04-18 | 2019-07-31 | Aharon Anat | Extracellular vesicles derived from t cells containing a chimeric antigen receptor |
| WO2020227369A1 (en) | 2019-05-06 | 2020-11-12 | Malcolm Thomas | Tailored hypoimmune nanovesicular delivery systems for cancer tumors |
| US12097222B2 (en) | 2019-06-06 | 2024-09-24 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| US11607428B2 (en) | 2019-06-06 | 2023-03-21 | Spiritus Therapeutics, Inc. | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases |
| US20210130782A1 (en) * | 2019-10-28 | 2021-05-06 | Augusta University Research Institute, Inc. | Engineered Exosomes to Detect and Deplete Pro-Tumorigenic Macrophages |
| WO2021092080A1 (en) * | 2019-11-04 | 2021-05-14 | Aruna Bio, Inc. | Extracellular vesicles and uses thereof for antibody delivery |
| CN111450249A (zh) * | 2020-03-09 | 2020-07-28 | 杨静悦 | miRNA-320a的表达促进物在制备抑制肿瘤细胞药物中的应用 |
| CA3190722A1 (en) * | 2020-08-05 | 2022-02-10 | Ohio State Innovation Foundation | Adapter polypeptides and methods of using the same |
| WO2022149779A1 (ko) * | 2021-01-11 | 2022-07-14 | 주식회사 엑소코바이오 | 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법 |
| WO2022158836A1 (ko) * | 2021-01-21 | 2022-07-28 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
| WO2023081109A1 (en) * | 2021-11-05 | 2023-05-11 | Malcolm Thomas | Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases |
| CN115887491A (zh) * | 2022-11-10 | 2023-04-04 | 中国药科大学 | 一种具有骨髓靶向功能的工程化双特异性外泌体/囊泡制剂及其制备方法和应用 |
| WO2024196812A1 (en) * | 2023-03-20 | 2024-09-26 | MAM Holdings of West Florida, L.L.C. | Mesenchymal stem cell-derived micro-ribonucleic acid-mediated treatments for the prevention and targeted treatment of cancer and other disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2454756C (en) * | 2001-08-17 | 2014-02-18 | Anosys, Inc. | Methods and compounds for the targeting of protein to exosomes |
| WO2004074437A2 (en) * | 2003-02-14 | 2004-09-02 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| IL161899A0 (en) * | 2004-05-10 | 2005-11-20 | Hoffman Arnold | Kit for treatment of cancer |
| EP3805269A1 (en) * | 2006-06-12 | 2021-04-14 | Aptevo Research and Development LLC | Single-chain multivalent binding proteins with effector function |
| WO2011097480A1 (en) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
-
2014
- 2014-10-17 US US15/029,395 patent/US20160243192A1/en not_active Abandoned
- 2014-10-17 WO PCT/US2014/061245 patent/WO2015058148A1/en not_active Ceased
- 2014-10-17 JP JP2016524060A patent/JP2016535009A/ja active Pending
- 2014-10-17 EP EP14854517.1A patent/EP3057662A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535009A5 (enExample) | ||
| Ortiz et al. | Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications | |
| Li et al. | Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer | |
| Yin et al. | Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy | |
| Vanmeerbeek et al. | Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology | |
| Braunstein et al. | Targeting toll-like receptors for cancer therapy | |
| AU2018352221B2 (en) | Peptides and nanoparticles for intracellular delivery of mRNA | |
| Sharma et al. | Dendrimer-mediated targeted delivery of rapamycin to tumor-associated macrophages improves systemic treatment of glioblastoma | |
| AU2016251415B2 (en) | C/EBP alpha saRNA compositions and methods of use | |
| JP6731405B2 (ja) | ウイルス粒子を用いた癌免疫療法 | |
| CN108392633B (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| JP2018508469A5 (enExample) | ||
| JP2017518302A5 (enExample) | ||
| JP2022092001A (ja) | 樹状細胞免疫療法 | |
| JP2019506862A5 (enExample) | ||
| US20210046156A1 (en) | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | |
| JP2012196206A5 (enExample) | ||
| US12516318B2 (en) | Targeting glioblastoma stem cells through the TLX-TET3 axis | |
| Carew et al. | Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas | |
| JP2017514800A5 (enExample) | ||
| Wang et al. | Current development of glioblastoma therapeutic agents | |
| JP2019531293A5 (enExample) | ||
| Baykara | Current therapies and latest developments in cancer treatment | |
| JP2016526021A5 (enExample) | ||
| JP2018509423A5 (enExample) |